Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox plus radiofrequency ablation versus radiofrequency ablation alone for unresectable hepatocellular carcinoma
2008-000963-41Phase 3Active
- Sponsor
- Imunon, Inc.
- Start
- Sep 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Imunon, Inc. Primary endpoints: Progression-free survival and Safety. Started Sep 2008; status: active.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-000963-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000963-41.